ClinicalTrials.gg
CompletedNCT06932055Updated Nov 5, 2026Results posted

A Phase II Pilot Study of the Trillium Full Face Mask

An interventional study of Trillium Full Face Mask and AirFit F20 in Obstructive Sleep Apnea, sponsored by Philips Clinical & Medical Affairs Global. Completed at 1 site in United States. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Philips Clinical & Medical Affairs Global (part of Philips) · Not applicable, Interventional, and Treatment

How we know

Updated Nov 5, 2026Now CompletedResults posted+10 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
21 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Sleep Apnea, Obstructive by Philips — none open to participants now, none under way, none of them phase 3. Sleep Apnea, Obstructive · Philips.

Enrollment
9th of 13
40 · median 45
Started
2025
the only one that year
No phase
13 of 13
none open now
Registered
12th of 13
by date

Among the 13 studies in Sleep Apnea, Obstructive by Philips, this one is the 9th largest by enrollment, is the only one that started in 2025, is one of 13 with no phase, and was the 12th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

None of the 13 studies in Sleep Apnea, Obstructive by Philips is open now. The open studies under Sleep Apnea, Obstructive, anywhere →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 21 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Sleep Apnea, Obstructive by Philips as a file.
02

Study summary

This will be a single-center, open-label randomized crossover design pilot study to evaluate the clinical safety, clinical performance, and clinical benefit of the Trillium full face mask

Read the detailed description

This will be a single-center, open-label randomized crossover design pilot study to evaluate the clinical safety, clinical performance, and clinical benefit of the Trillium FFM (Full Face Mask). Subjects meeting all eligibility criteria will be enrolled and will be randomized. Based on their randomization, subjects will be asked to use either a new AirFit F20 mask or the Trillium investigational mask for approximately 15 consecutive days (±3 days) of use. They will return for a follow-up visit to complete surveys about their experience during the first treatment period. Subjects will then be crossed over to the other mask (i.e., AirFit F20 or Trillium) per the randomization assignment. Following a second 15-day period of home use, subjects will return for a final visit to complete surveys about their experience in the second treatment period and conclude participation in the investigation.

03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
21 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 21-85 years (inclusive)
  • Diagnosed with OSA, Established on PAP therapy for ≥90 days at the time of consent
  • Currently prescribed and using fixed pressure, Auto CPAP, or BiPAP therapy on a regular basis (average PAP usage of ≥4 hours/night, ≥4 days per week for ≥3 months)
  • Able to read, write, speak and understand English
  • Willing and able to provide
  • Willing and able to follow instructions and complete all activities required by the study
  • Able to remove a sleep apnea mask without assistance
  • Currently using a ResMed PAP therapy device with a connection to ResMed's AirView system
  • Currently using ResMed AirFit F20

Exclusion criteria

Exclusion Criteria:

  • Significant risk of aspiration (i.e., active vomiting or taking a prescription drug that induces vomiting)
  • Known allergy to silicone, latex, polyamide (nylon), spandex, polyurethane, acetal, polycarbonate, or polypropylene
  • Active infection or inflammation in an area in contact with the mask
  • Recent head or facial surgery unless cleared by a healthcare provider to resume regular therapy
  • Planned head or facial surgery during the study
  • Any congenital or acquired craniofacial malformations or abnormalities, acute trauma, or burns that would interfere with the mask's placement or ability to deliver therapy
  • Employee or family member who works for Philips or any of its direct competitors in the sleep industry
  • Prescribed oxygen at night or continuously
  • Currently participating in another interventional research study or planned participation in another interventional clinical research study during the trial period
  • Prescribed an ASV (adaptive servo-ventilation) device
  • Prescribed mechanical ventilation
  • Pre-existing conditions such as bullous lung disease, pathologically low blood pressure, bypassed upper airway, pneumothorax, pneumocephalus, cerebral spinal fluid (CSF) leaks,
  • Any unstable medical condition (e.g., uncontrolled cardiac, lung, or neurological disease) or limitation that would affect the participant's ability to complete trial activities
  • Experiencing any acute illness (e.g., acute sinusitis, ear or eye infections, upper respiratory infections, pharyngitis, bronchitis, pleurisy, pneumonia, or facial dermatitis) that would impact their ability to use the mask and/or PAP therapy during the trial
  • Pregnant (self-report)
  • Advised by a health care provider to avoid magnets
  • Patient or patient's household member, caregiver or bed partner in close vicinity that have implanted devices that may be affected by magnets, including but not limited to:

    • Pacemakers
    • Implantable cardioverter defibrillators (ICD)
    • Neurostimulators
    • Magnetic metallic implants/electrodes/valves placed in upper limbs, torso, or higher (i.e., neck and head)
    • Cerebral spinal fluid (CSF) shunts (e.g., ventriculo peritoneal (VP) shunt)
    • Aneurysm clips
    • Embolic coils
    • Intracranial aneurysm intravascular flow disruption devices
    • Metallic cranial plates
    • Screws, burr hole covers, and bone substitute devices
    • Metallic splinters in the eye
    • Ocular implants (e.g., glaucoma implants, retinal implants)
    • Certain contact lenses with metal
    • Implants to restore hearing or balance that have an implanted magnet (such as cochlear implants, implanted bone conduction hearing devices, and auditory brainstem implants
    • Magnetic denture attachments
    • Metallic gastrointestinal clips
    • Metallic stents (e.g., aneurysm, coronary, tracheobronchial, biliary)
    • Implantable ports and pumps (e.g., insulin pumps)
    • Hypoglossal nerve stimulators
    • Implanted devices labeled as MR (magnetic resonance) unsafe
    • Magnetic metallic implants not labeled for MR or not evaluated for safety in a magnetic field
  • Paralysis of the hemi-diaphragm
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Trillium then AirFit F20 sequence

    Participants will use Trillium for the first treatment period and AirFit F20 for the second treatment period

    Device: Trillium Full Face Mask

  • Experimental
    Airfit F20 then Trillium sequence

    Participants will use AirFit F20 for the first treatment period and Trillium for the second treatment period

    Device: AirFit F20

Interventions

  • DeviceTrillium Full Face Mask

    The Trillium Full Face Mask (FFM) (Philips Respironics, Murrysville, PA) is an over-the-nose, full-face mask with the hose connection in the front. The mask is used with a positive airway pressure (PAP) therapy device and covers both the nose and mouth, ensuring pressurized air is delivered directly into the patient's airways.

    Also known as: Trillium

  • DeviceAirFit F20

    The AirFit F20 (ResMed, San Diego, California) is an externally placed vented mask covering the mouth and the nose of the patient. It provides a seal such that pressure from a positive pressure source is directed to the patient's nose and/or mouth. The mask connects via a standard conical connector to a conventional air delivery hose, which in turn connects to the positive pressure source. The mask is held in place with an adjustable headgear that straps the mask to the face. The AirFit F20 mask system comprises four subassemblies: cushion, frame, elbow and headgear. The elbow incorporates the vent array and anti-asphyxia valve safety features.

06

What researchers measure

Primary outcomes

  1. Median Unintentional Leak During Trillium Mask Use

    Unintentional leak was obtained from positive airway pressure device data during the approximately 15-day Trillium mask treatment period. For each participant, the median unintentional leak was calculated. The reported result is the mean of the participant-level median values and its 95% confidence interval. Lower values indicate less unintentional leak. The result was considered acceptable if the upper limit of the 95% confidence interval was less than 24 L/min.

    Time frame: During the approximately 15-day Trillium mask treatment period

Other outcomes

  1. Expected Adverse Device Effects

    Number of participants with expected adverse device effects during the approximately 15-day Trillium mask treatment period. Expected effects included skin effects, oronasal dryness, eye-related side effects, anxiety, allergic reaction, and headache.

    Time frame: Approximately 15-day Trillium mask treatment period

  2. Comfort of Breathing During Trillium Mask Use

    After the Trillium mask treatment period, participants rated their satisfaction with comfort of breathing on a scale from 0 to 10, where 0 indicated extremely dissatisfied, 5 indicated neutral, and 10 indicated extremely satisfied. The reported result is the mean rating across participants and its 95% confidence interval. Higher scores indicate greater satisfaction. The result was considered acceptable if the lower limit of the 95% confidence interval was at least 7.5.

    Time frame: After approximately 15-day Trillium mask treatment period

  3. Average Daily PAP Device Use Across All Study Days

    Average daily PAP device use was calculated for each participant across all study days in each treatment period, including days with no recorded device use, and expressed in hours per day. The reported results are the mean and 95% confidence interval across participants for each mask. Higher values indicate greater device use.

    Time frame: During each approximately 15-day mask treatment period

  4. Apnea-Hypopnea Index (AHI)

    Residual apnea-hypopnea index was obtained from PAP device data during each treatment period and expressed as the number of apnea and hypopnea events per hour. The reported results are the mean and 95% confidence interval across participants for each mask. Lower values indicate fewer residual respiratory events.

    Time frame: During each approximately 15-day mask treatment period

  5. Epworth Sleepiness Scale Total Score

    The Epworth Sleepiness Scale is an 8-item questionnaire assessing the likelihood of dozing during common daily situations. Each item is scored from 0 (would never doze) to 3 (high chance of dozing). Item scores are summed to produce a total score ranging from 0 to 24 points. Higher scores indicate greater daytime sleepiness.

    Time frame: After each approximately 15-day mask treatment period

  6. EQ-5D-3L Summary Index

    The EQ-5D-3L (European Quality of Life-5D) is a generic measure of health status. The descriptive system assesses five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three response levels (1 = no problems, 2 = some problems, and 3 = extreme problems). Responses were converted to a single summary index using the U.S. value set. Index scores range from -0.109 to 1.000, with higher scores indicating better health status and 1 representing full health.

    Time frame: After each approximately 15-day mask treatment period

07

Results

Posted Sep 28, 2026
Limitations and caveats
This pilot study had a small, unpowered sample, limiting reliability. Enrollment was limited to established PAP therapy users already using AirFit F20, which may have introduced familiarity bias, underestimated effect sizes, and limited generalizability to new PAP users or users of other masks. AirFit F20 was the only comparator, so findings may not represent other competitor masks.

Participant flow

A total of 40 participants were enrolled, and 38 completed for a safety analysis data set of n=40 and a performance analysis data set of n=38 participants. The first participant was enrolled on 15-Jul-2025 and last participant completed the study on 19-Aug-2025. Participants were recruited from Florida Lung \& Sleep Associates

Participant flow — Overall Study
MilestoneTrillium Then AirFit F20 SequenceAirfit F20 Then Trillium Sequence
Started2020
Completed1919
Not completed11

Outcome measures

PrimaryMedian Unintentional Leak During Trillium Mask Use

Unintentional leak was obtained from positive airway pressure device data during the approximately 15-day Trillium mask treatment period. For each participant, the median unintentional leak was calculated. The reported result is the mean of the participant-level median values and its 95% confidence interval. Lower values indicate less unintentional leak. The result was considered acceptable if the upper limit of the 95% confidence interval was less than 24 L/min.

Time frame:
During the approximately 15-day Trillium mask treatment period
Reported as:
Mean · L/min
Median Unintentional Leak During Trillium Mask Use
L/minTrillium
Median Unintentional Leak During Trillium Mask Use12.14 (5.10 to 19.19)
Other pre-specifiedExpected Adverse Device Effects

Number of participants with expected adverse device effects during the approximately 15-day Trillium mask treatment period. Expected effects included skin effects, oronasal dryness, eye-related side effects, anxiety, allergic reaction, and headache.

Time frame:
Approximately 15-day Trillium mask treatment period
Reported as:
Count of participants · Participants
Expected Adverse Device Effects
ParticipantsTrillium
Expected Adverse Device Effects0
Other pre-specifiedComfort of Breathing During Trillium Mask Use

After the Trillium mask treatment period, participants rated their satisfaction with comfort of breathing on a scale from 0 to 10, where 0 indicated extremely dissatisfied, 5 indicated neutral, and 10 indicated extremely satisfied. The reported result is the mean rating across participants and its 95% confidence interval. Higher scores indicate greater satisfaction. The result was considered acceptable if the lower limit of the 95% confidence interval was at least 7.5.

Time frame:
After approximately 15-day Trillium mask treatment period
Reported as:
Mean · points on a 0-10 scale
Comfort of Breathing During Trillium Mask Use
points on a 0-10 scaleTrillium
Comfort of Breathing During Trillium Mask Use9.03 (8.44 to 9.61)
Other pre-specifiedAverage Daily PAP Device Use Across All Study Days

Average daily PAP device use was calculated for each participant across all study days in each treatment period, including days with no recorded device use, and expressed in hours per day. The reported results are the mean and 95% confidence interval across participants for each mask. Higher values indicate greater device use.

Time frame:
During each approximately 15-day mask treatment period
Reported as:
Mean · hours/day
Average Daily PAP Device Use Across All Study Days
hours/dayTrilliumAirFit F20
Average Daily PAP Device Use Across All Study Days6.62 (6.13 to 7.11)6.57 (6.07 to 7.06)
Statistical analysis
  • Trillium vs AirFit F20 · Mean difference (final values): 0.05 · 95% CI -0.31 to 0.41The estimated difference was calculated as Trillium minus AirFit F20. Positive values indicate greater average daily device use with Trillium.
Other pre-specifiedApnea-Hypopnea Index (AHI)

Residual apnea-hypopnea index was obtained from PAP device data during each treatment period and expressed as the number of apnea and hypopnea events per hour. The reported results are the mean and 95% confidence interval across participants for each mask. Lower values indicate fewer residual respiratory events.

Time frame:
During each approximately 15-day mask treatment period
Reported as:
Mean · events/hour
Apnea-Hypopnea Index (AHI)
events/hourTrilliumAirFit F20
Apnea-Hypopnea Index (AHI)2.28 (1.47 to 3.08)2.41 (1.30 to 3.51)
Statistical analysis
  • Trillium vs AirFit F20 · Mean difference (final values): -0.13 · 95% CI -0.66 to 0.40The estimated difference was calculated as Trillium minus AirFit F20. Negative values indicate lower residual AHI with Trillium.
Other pre-specifiedEpworth Sleepiness Scale Total Score

The Epworth Sleepiness Scale is an 8-item questionnaire assessing the likelihood of dozing during common daily situations. Each item is scored from 0 (would never doze) to 3 (high chance of dozing). Item scores are summed to produce a total score ranging from 0 to 24 points. Higher scores indicate greater daytime sleepiness.

Time frame:
After each approximately 15-day mask treatment period
Reported as:
Mean · points on a 0-24 scale
Epworth Sleepiness Scale Total Score
points on a 0-24 scaleTrilliumAirFit F20
Epworth Sleepiness Scale Total Score5.50 (4.07 to 6.93)5.92 (4.58 to 7.27)
Statistical analysis
  • Trillium vs AirFit F20 · Mean difference (final values): -0.42 · 95% CI -1.65 to 0.81Trillium minus AirFit F20. The estimate is the descriptive mean within-participant treatment difference in ESS total scores.
Other pre-specifiedEQ-5D-3L Summary Index

The EQ-5D-3L (European Quality of Life-5D) is a generic measure of health status. The descriptive system assesses five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three response levels (1 = no problems, 2 = some problems, and 3 = extreme problems). Responses were converted to a single summary index using the U.S. value set. Index scores range from -0.109 to 1.000, with higher scores indicating better health status and 1 representing full health.

Time frame:
After each approximately 15-day mask treatment period
Reported as:
Mean · EQ-5D-3L index points
EQ-5D-3L Summary Index
EQ-5D-3L index pointsTrilliumAirFit F20
EQ-5D-3L Summary Index0.88 (0.81 to 0.94)0.89 (0.83 to 0.94)
Statistical analysis
  • Trillium vs AirFit F20 · Mean difference (final values): -0.01 · 95% CI -0.04 to 0.02Trillium minus AirFit F20. The estimate is the descriptive mean within-participant treatment difference in EQ-5D-3L Summary Index values.

Adverse events

Collected over During the approximately 15-day treatment period for each mask. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trillium0/39 (0%)1/39 (2.6%)0/39 (0%)
AirFit F200/39 (0%)0/39 (0%)1/39 (2.6%)
Most frequent serious events
Most frequent serious events
EventTrilliumAirFit F20
Bilateral lower extremity weaknessNervous system disorders1/390/39
Most frequent other events
Most frequent other events
EventTrilliumAirFit F20
dizziness/diaphoresis/dyspneaGeneral disorders0/391/39

Baseline characteristics

Age, Continuous
Age, Continuous(years)Trillium Then AirFit F20 SequenceAirfit F20 Then Trillium SequenceTotal
Mean61.7 ± 14.1557.9 ± 13.9359.8 ± 13.99
Sex: Female, Male
Sex: Female, Male(Participants)Trillium Then AirFit F20 SequenceAirfit F20 Then Trillium SequenceTotal
Female7411
Male131629
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trillium Then AirFit F20 SequenceAirfit F20 Then Trillium SequenceTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American347
White171532
More than one race000
Unknown or Not Reported011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Trillium Then AirFit F20 SequenceAirfit F20 Then Trillium SequenceTotal
Hispanic or Latino7815
Not Hispanic or Latino121123
Unknown or Not Reported112
08

Study locations

1 site
  • Florida Lung & Sleep Associates
    Lehigh Acres, Florida 33971, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Aug 2025, 1 month.

Results were first posted in Sep 2026, 1 year 1 month after primary completion.

Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 1 month is below that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 17, 2025
StartActual
Jul 15, 2025
Primary completionActual
Aug 19, 2025
CompletionActual
Aug 19, 2025
Results first posted
Sep 28, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Withheld→Completed
changed Sep 28, 2026
Results
Results posted
posted Sep 28, 2026
Sites
1 site added — first site in United States
Show site
  • Florida Lung & Sleep Associates · Lehigh Acres, United States
Nov 5, 2026
Start date
Set to Jul 15, 2025 (actual)
Sep 28, 2026
Primary completion
Set to Aug 19, 2025 (actual)
Sep 28, 2026
Study completion
Set to Aug 19, 2025 (actual)
Sep 28, 2026
Eligibility
Revised
Sep 28, 2026
Interventions
Arms or interventions changed
Sep 28, 2026
Documents
Title
[Trial of device that is not approved or cleared by the U.S. FDA]→A Phase II Pilot Study of the Trillium Full Face Mask
Sep 28, 2026
Sponsor
[Redacted]→Philips Clinical & Medical Affairs Global
Sep 28, 2026
Show all 2 updates
  1. Nov 5, 2026
    1 site added — first site in United States
    Show site
    • Florida Lung & Sleep Associates · Lehigh Acres, United States
    + 3 other changes: verification date, oversight details and design details
  2. Sep 28, 2026
    Withheld→Completed
    Results posted
    Start date Set to Jul 15, 2025 (now actual)
    Primary completion Set to Aug 19, 2025 (now actual)
    Study completion Set to Aug 19, 2025 (now actual)
    Eligibility Revised
    Interventions Arms or interventions changed
    Sponsor [Redacted]→Philips Clinical & Medical Affairs Global
    Title [Trial of device that is not approved or cleared by the U.S. FDA]→A Phase II Pilot Study of the Trillium Full Face Mask
    + 9 other changes: index terms, registry dates, verification date, oversight details, description, conditions, design details, secondary outcomes and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06932055
Collaborators
Florida Lung & Sleep Associates
Responsible party
Sponsor
First posted
Apr 17, 2025
Start date
Jul 15, 2025
Primary completion
Aug 19, 2025
Completion
Aug 19, 2025
Results posted
Sep 28, 2026
Last update
Nov 5, 2026

Study contacts

Alaa El-Gendy
principal investigator · Florida Lung & Sleep Associates

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion